Uterine conservative surgery vs hysterectomy for placenta accreta spectrum disorders– a systematic review and meta-analysis

Running title: Conservative surgery for placenta accreta spectrum disorders – a systematic review

Gabriel Moreira Lino[1], Pauliana Valéria Machado Galvão[2], George Alessandro Maranhão Conrado[1]

[1]University of Pernambuco, Serra Talhada, Brazil

[2]Faculty of Medical Sciences, University of Pernambuco, Recife, Brazil

Corresponding author: **Pauliana Valéria Machado Galvão**

Address: R. Arnóbio Marquês, 310 - Santo Amaro, Recife - PE, 50100-130

Telephone number: +55 81 996604662

Email address: pauliana.galvao@upe.br

ABSTRACT

Background

Resection and reconstruction of the uterus may be an alternative to hysterectomy in placenta accreta spectrum disorders. We aimed to review whether surgical and maternal outcomes were comparable between these techniques.

Methods

The Cochrane Library, PubMed, and Embase databases were searched until 1 January 2025 for randomized controlled trials (RCT) and observational studies comparing uterine conservative surgery to hysterectomy. The risk of bias was assessed with ROB-2 or ROBINS-I, and the quality of evidence with GRADE. The main outcomes were blood loss and transfusion, reoperation, intraoperative visceral organ injury, and long-term complications.

Main results

We included one RCT and eleven nonrandomized studies. Compared to hysterectomy, conservative surgery may result in similar intraoperative blood loss (MD -320.89 mL, 95% CI -574.95 to -66.82; 1 RCT and 3 prospective studies, 637 women; I^2= 14%; low-certainty evidence) and transfused red blood cell packs (MD -0.70 packs, 95% CI -1.28 to -0.12; 1 RCT and 4 prospective studies, 649 women; I^2= 0%; low-certainty evidence). There may be no difference in intraoperative visceral organ injury, reoperation, and duration of surgery (low-certainty evidence). Other outcomes were uncertain because of very low evidence.

Conclusions

On the basis of low evidence, conservative surgery did not increase the risk of clinically important harm compared to hysterectomy, with the benefit of uterus preservation. Further RCTs are needed to reach definitive conclusions about potential benefits. To improve the quality of evidence from low to moderate, a trial with an additional 181 participants in the conservative surgery arm would be necessary to avoid downgrading for imprecision.

Keywords: Placenta accreta. Surgery. Fertility. One-step surgery. Triple-P procedure. Conservative management.

Registration: PROSPERO CRD42024601117.

INTRODUCTION

Until recently, hysterectomy was virtually the only management option for placenta accreta spectrum disorder (PAS). However, as the prevalence of PAS has increased to affect approximately 1 in every 313 women undergoing cesarean section, the growing number of women wishing to preserve fertility has prompted investigation into alternative strategies for uterine preservation[1]. Currently, leaving the placenta in situ is one of the most utilized alternatives to hysterectomy, although it requires high-resource settings and continuous long-term monitoring[2,3]. In this context, uterus-preserving surgery (also referred to as one-step surgery, triple P procedure, or MOSCUS, according to variations in the technique proposed by individual authors) has been developed to provide immediate surgical resolution of PAS during cesarean delivery[4].

This technique involves removing the invaded myometrium and reconstructing the uterine wall, with or without preventive surgical devascularization[2,4]. However, there is still low certainty regarding its efficacy and safety. Therefore, this review aims to summarize the available evidence on this conservative surgical technique, comparing it to hysterectomy in patients diagnosed with PAS who wish to preserve fertility.

METHODS

Criteria for considering studies for this review

We considered randomized controlled trials (RCT) and nonrandomized studies of interventions comparing uterine conservative surgery to hysterectomy in patients with placenta accreta, increta, or percreta. To be included the surgical technique must have involved resection of abnormally invasive placenta and myometrium and reconstruction of the uterine wall. Therefore, we excluded studies that provided fertility preservation by manual removal of the

placenta followed by vascular control procedures, such as uterine compressive sutures, tourniquets, and uterine devascularization.

The following critical outcomes were considered:

1. Intraoperative blood loss;
2. Number of transfused packs of red blood cell or women needing transfusion;
3. Intraoperative visceral organ injury (bladder injury, bowel injury, ureter injury, and vascular injury)
4. Reoperation;
5. Long-term complications of surgery (fistula, premature ovarian insufficiency, urinary dysfunction, dysmenorrhea);

The secondary outcomes of the review were:

1. Duration of surgery;
2. Duration of hospital stay;
3. Admission to intensive care unit;
4. Postoperative infection.

Studies had to report at least one of the primary outcomes to be eligible for the review.

Search methods for identification of studies

We searched for published studies up to January 2025, on PubMed, Embase, and the Cochrane Library using the terms: (one step conservative surgery OR uterine conservative-resective surgery OR uterus resection OR uterine resective surgery OR uterine conservative surgery OR uterus conservation surgery OR uterine preserving surgery OR fertility sparing surgery OR fertility preserving surgery OR triple p procedure OR triple p) and (placenta accreta spectrum OR placenta increta OR placenta percreta OR abnormally invasive placenta OR morbidly adherent placenta). There were no language restrictions.

Data collection and analysis

Two review authors (GL and GC) independently screened the title and abstract of the identified records. If one of the authors considered the record eligible, both assessed the full text. Subsequently, the authors selected and extracted information about study characteristics to a previously cross-validated file.

Risk of bias assessment in included studies

Two review authors (GL and GC) used the Cochrane risk-of-bias tool for randomized trials (RoB 2), version of August 2019, to assess the risk of bias/quality of the included randomized trials[5]. The ROBINS-I V2 tool, 2024, was used instead for nonrandomized studies of interventions[6]. We evaluated the overall risk of bias in each study based on three primary outcomes (blood loss, transfusion, and intraoperative visceral organ injury). For the assessment of the risk of bias in nonrandomized studies, the intention-to-treat analysis section was considered. Dropouts, group conversions, or loss to follow-up below 5% were judged as low risk of bias. Additionally, when more than 50% of the weight of the studies contributing to an estimate was from studies at high risk of bias, the overall certainty of evidence was downgraded.

Synthesis methods

We used an inverse-variance random effects model, reporting dichotomous data as Relative Risk (RR) with 95% Confidence intervals (CI) and continuous outcomes as mean differences (MD) and 95% CI. Statistical heterogeneity was assessed by calculating tau (DerSimonian-Laird estimator and Jackson method for confidence interval of tau^2), I^2, and Cochran's Q; I^2 higher than 50% was considered a significant indicator of heterogeneity. We investigated publication bias with funnel plots and Egger’s test.

Studies that reported medians and interquartile range were transformed using an internal function of the meta package, following what was described by Luo and collaborators[7]. We stratified our analyses based on the risk of bias (high and not high risk of bias). Primary results in every section only included studies with randomized design or that were not at high risk of bias. Subsequent analyses reported the estimated effect including the remaining studies, except when the results of both analyses were uncertain, making it unnecessary to report them separately.

Analyses were conducted in R, with the packages meta and metafor[8,9].

Certainty of the evidence assessment

The overall certainty of the evidence for each outcome was assessed by one reviewer (GL) using the GRADE approach. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) handbook was followed to determine the quality of the evidence of the analyses conducted[10]. For the evaluation of imprecision, the update provided in 2022 was followed[11]. The Review Information Size was determined using conventional power analysis ($\alpha = 0.05$; $\beta = 0.2$), taking into account the range of standard deviations from randomized controlled trials and medium to low risk of bias studies.

RESULTS

Results of the search

We initially identified 640 records in our search. Of these, 106 were deemed potentially eligible, and 12 (only one RCT) were ultimately included in the review. The primary reasons for exclusion were inadequate surgical techniques (manual placental removal or failure to report surgical methods), poor study design (such as case series, reports, reviews, editorials, and

letters), absence of relevant outcome data specified in the review protocol, and not comparing conservative surgery to hysterectomy (such as comparing to manual removal of the placenta).



Figure 1 Prisma 2020 flow diagram of study selection

Included studies

Table 1 summarizes the characteristics of the included studies. One RCT and eleven non-randomized studies were included, four of which had prospective designs. Moreover, some studies reported the PAS FIGO clinical grading[12], with patients of every grade in both arms.

The average maternal age ranged from 30 to 37 years, with most women having had one or two previous cesarean sections.

Preventive vascular interventions before myometrial resection were utilized in three of the included studies. Detailed descriptions of methods, eligibility criteria, and participants are available in Supplementary Table S1. The most common criteria for eligibility for uterine conservative surgery were: (1) at least 2 cm of healthy myometrium in the anterior uterine wall, (2) more than 50% of the uterine circumference without PAS involvement, and (3) the ability to safely dissect the bladder from the uterus. Most studies followed the surgical technique described as one-step surgery[4].

Table 1 – Summary of characteristics of included studies

Author (Year)	Country	Study design	Sample size (CS; HT)	PAS FIGO grading (n)		Maternal age (y)		Previous cesarean deliveries (n)		Preventive vascular intervention	Risk of bias
				CS	HT	CS	HT	CS	HT		
Nieto-Calvache 2024[13]	Multicenter	RCT, not blinded	60 (29;31)	Grade 1 2 Grade 2 18 Grade 3A 3 Grade 3B-C 4	1 20 0 3	33.45±4.56	33.13 ±4.26	1: 14 2: 13	18 13	No	Moderate risk
Nieto-Calvache 2023[14]	Multicenter	NRSI, prospective design	75 (64;11)	-	-	33 (26−38)	31 (29−37)	-	-	No	Moderate risk
Paping 2024[15]	Multicenter	NRSI, retrospective design, prospectively-collected data	224 (38;186)	Grade 1 10 Grade 2 13 Grade 3A 14 Grade 3B-C 1	21 46 60 59	34 (30–37)	35 (31–39)	2 (1–3)	2 (1–2)	No	Moderate risk

Abouda 2024[16]	Single center	NRSI, prospective design	12 (6;6)	-	-	37.17±2.93	33.67±3.07	4±0.89	2.83±0.98	No	Moderate risk
van Beekhuizen 2021[17]	Multicenter	NRSI, retrospective design, prospectively collected data	278 (26;252)	Grade 1 3 Grade 2 2 Grade 3A 18 Grade 3B-C 3	31 52 102 66	-	-	-	-	No	Moderate risk
Vuong 2024[18]	Single center	NRSI, retrospective design	296 (217;79)			33.17 ± 4.77	33.68 ± 4.94	1: 125 2: 73	36 36	No	High risk
Aryananda 2023[19]	Single center	NRSI, retrospective design	126 (91;35)	Grade 1 16 Grade 2 54 Grade 3A 15 Grade 3B-C 6	0 7 10 18	33 (22–46)	33 (22–42)	2 (1–3)	2 (1–3)	No	High risk

Aryananda 2022[20]	Single center	NRSI, retrospective design	234 (200;34)	-	-	33 (19–44)	35 (26–41)	1: 147 2: 42	1: 20 2: 13	Yes: internal iliac artery ligation	High risk
Jafari 2022[21]	Single center	NRSI, retrospective design	68 (44;24)	-	-	33.23 ± 4.72	32.54 ± 5.69	-	-	No	High risk
Durukan 2021[22]	Single center	NRSI, retrospective design	65 (23;42)	-	-	33.1 ± 5.4	34.1 ± 5.4	2.0 ± 1.1	2.1 ± 0.9	No	High risk
Üstünyurt 2020[23]	Single center	NRSI, retrospective design	97 (30;67)	-	-	31.1±5.4	33.2±4.7	-	-	Yes: Intrauterine balloon tamponade	High risk
Kilicci 2018	Single center	NRSI, retrospective design	51 (22;29)	-	-	32.3 ±5.3	32.45± 4.7	1.6 ±0.9	1.8 ±0.6	No	High risk

Risk of bias

An overview of the risk of bias is provided in Table 1. The included RCT was classified as having a moderate risk of bias due to the lack of blinding and important patient crossover/drop-out. Nearly all non-randomized studies were deemed to be at high risk of bias, as the selection of patients for surgery relied primarily on intraoperative assessments based on the topography of the invasive placenta. This could introduce serious selection bias if not prospectively determined. Additionally, few studies reported potential confounding variables or adjusted their analyses as necessary.

An investigation into publication bias revealed that retrospective studies, which were at high risk of bias, tended to report higher mean differences with larger standard errors compared to studies with moderate to low risk of bias, as well as to the RCT (Figure S1). However, Egger's Test did not detect significant publication bias affecting the analysis (p-value = 0.2041).

Analysis of intervention

1 Conservative surgery vs Hysterectomy

1.1 Intraoperative blood loss

Conservative surgery may result in similar intraoperative blood loss compared to hysterectomy (MD -320.89 mL, 95% CI -574.95 to -66.82; 1 RCT and 3 NRSI, 637 women; I^2= 14%; low-certainty evidence). By including studies at high risk of bias, the difference in blood loss is larger, but we are very uncertain about this estimate (MD -497.33 mL, 95% CI -755.37 to -226.17; 1 RCT and 7 NRSI; I^2= 73%; very low-certainty evidence)(Figure 2).



Figure 2 Comparison of uterine conservative surgery vs hysterectomy on intraoperative blood loss in women with placenta accreta spectrum disorders

1.2 Number of transfused packs of red blood cells (pRBCs) and number of women needing transfusion

The number of transfused pRBCs per patient may be similar in conservative surgery compared to hysterectomy (MD -0.70 packs, 95% CI -1.28 to -0.12; 1 RCT and 4 NRSI, 649 women; I^2= 0%; low-certainty evidence). We are very uncertain that this benefit could be slightly larger (MD -1.15 packs, 95% CI -1.64 to -0.65; 1 RCT and 9 NRSI; I^2= 20%; very low-certainty evidence)(Figure 3). Moreover, there may be no difference in the number of patients needing blood transfusion (RR 0.87, 95% CI 0.67 to 1.13; 1 RCT and 1 NRSI, 135 women; I^2= 0%; low-certainty evidence) or very uncertainly fewer women will require transfusion (RR 0.82, 95% CI 0.74 to 0.91; 1 RCT and 4 NRSI; I^2= 0%; very low-certainty evidence).



Figure 3 Comparison of uterine conservative surgery vs hysterectomy on the number of transfused pRBCs per patient in women with placenta accreta spectrum disorders

1.3 Intraoperative visceral organ injury

There may be no difference in the risk of bladder injury (RR 0.36, 95% CI 0.12 to 1.07; 1 RCT and 4 NRSI, 649 women; I^2= 0%; low-certainty evidence) or very uncertainly lower risk of bladder injury (RR 0.32, 95% CI 0.19 to 0.54; 1 RCT and 6 NRSI; I^2= 0%; very low-certainty evidence)(Figure 4). In the two studies that investigated ureter injuries, no cases were present in either arm (2 NRSI, 87 women; very low-certainty evidence). No cases of bowel injury were reported with conservative surgery and 7 were reported with hysterectomy (RR 0.17, 95% CI 0.02 to 1.65; 3 NRSI; I^2= 17%; very low-certainty evidence).



Figure 4 Comparison of uterine conservative surgery vs hysterectomy on bladder injury in women with placenta accreta spectrum disorders

1.4 Reoperation

Risk of surgical reintervention was not clear (RR 0.50, 95% CI 0.07 to 3.51; 1 RCT and 3 NRSI; I^2= 0%; very low-certainty evidence)(RR 0.45, 95% CI 0.05 to 3.23; 1 RCT and 5 NRSI; I^2= 0%; very low-certainty evidence).

1.5 Long-term complications of surgery

We are uncertain whether the type of surgery influences the formation of vesicovaginal fistula (RR 1.40, 95% CI 0.16 to 12.08; 1 RCT and 1 NRSI, 294 women; I^2= 0%; very low-certainty evidence).

1.6 Duration of surgery

There may be no difference in the duration of surgery (MD -36.31 minutes, 95% CI -73.06 to 0.43; 1 RCT and 2 NRSI, 147 women; I^2= 54%; low-certainty evidence) or very uncertainly conservative surgery may be shorter, however high heterogeneity limits the interpretation of this analysis (MD -26.45 minutes, 95% CI -45.35 to -7.56; 1 RCT and 6 NRSI; I^2= 89%; very low-certainty evidence)(Figure 5).



Figure 5 Comparison of uterine conservative surgery vs hysterectomy on the duration of surgery in women with placenta accreta spectrum disorders

1.7 Duration of hospital stay

We are uncertain whether there is a difference in the duration of hospital stay (MD -0.39 days, 95% CI -0.87 to 0.08; 1 RCT and 4 NRSI; I^2=33%; very low-certainty evidence). Duration of hospital stay could be subjected to individual protocols in each hospital and not related to the surgeries investigated.

1.7 Admission to the intensive care unit (ICU)

The risk of ICU admission is uncertain (RR 1.11, 95% CI 0.83 to 1.47; 1 RCT and 4 NRSI; I^2= 0%; very low-certainty evidence).

Certainty of evidence

The certainty of the evidence ranged from low to very low, according to the GRADE assessment. Whenever the analysis included nonrandomized studies, the evidence started at low. If only trial data were included, the Review Information Size (RIS) necessary to not downgrade for imprecision, for equally divided groups, would be: 166 to 594 participants for pRBC, and 210 to 4908 participants for blood loss, assuming moderate to small effects for the outcomes.

DISCUSSION

Summary of main results

Conservative surgery has the advantage of preserving the uterus with surgical outcomes that may be similar to hysterectomy. The effect on reoperation, admission to the intensive care unit, and vesicovaginal fistula, is uncertain, as the 95% CI included substantial benefit and substantial harm. Notably, the risk of intraoperative visceral injury and the number of transfused red blood cell packs may be lower or similar to hysterectomy. It should also be clear that patients had to have a specific PAS topography to be eligible for conservative surgery, with generally at least 2 cm of healthy myometrium on the anterior uterine wall, >50% of the uterine circumference free of PAS, without vesicouterine fibrosis, or extensive invasion of the lower anterior uterine wall.

Limitations of the evidence included in the review

The most important limitation of our study is the inclusion of nonrandomized studies of interventions. Major limitations that future trials on PAS would face are the low incidence of PAS, which requires longer recruitment and results in smaller samples, the long-term follow-up needed to determine patient-centered outcomes, and the specific placenta topography that limits the number of eligible women to be recruited. It should be clear that nonrandomized studies are better at evaluating potential harm than potential benefit[24]. Combining RCT data with moderate-risk observational studies was judged as necessary in our review once a review of randomized trials could not answer the proposed comparisons, as we intended to provide reasonable point estimates for minimal sample size calculations, and a safety overview. Therefore, we limited our conclusions to evaluating increased harm rather than demonstrating a potential superiority of conservative surgery.

Inherent consequences of results drawn from these studies are uncontrolled confounding and suboptimal outcome reporting. Even after excluding high-risk studies from the main analysis, the confidence in the estimates provided was low. If only the data of the randomized trial were analyzed, the small sample size and wide confidence intervals would make it unreasonable to assume any given effect for uterine conservative surgery.

Additionally, strict eligibility criteria for participants should not be overlooked, as it would be incorrect to assume that this surgery could substitute hysterectomy in all PAS cases. Another limitation was the lack of patient-driven outcomes in the included studies. However, it could be argued that uterus preservation (with reasonable safety) would be the most prominent outcome for patients.

Agreements and disagreements with other studies or reviews

The success rate of conservative surgery in preserving fertility was reviewed elsewhere, and hence, was not one of our outcomes of interest[25]. Notably, subsequent pregnancy is possible, however, adverse maternal outcomes or recurrence of PAS was reported in nearly 20% of patients, and hysterectomy was necessary for around 2% of all women[25,26]. Such findings should be interpreted in the context of very low-certainty evidence due to the limitations of these studies.

Our results add substantially to the initial assessment from FIGO in 2018, in which it was suggested that leaving the placenta in situ was a valid management option for women desiring to preserve fertility while uterine conservative surgery remained unclear at that moment[2]. Here we present both randomized and prospective nonrandomized data that suggest the safety of the uterine conservative surgery. Leaving the placenta in situ was recently further validated by the PACCRETA study, a large nonrandomized, multicenter, prospective, parallel-group study[27]. In theory, considering both nonsurgical and surgical conservative management for PAS would be ideal for women desiring to preserve fertility, as these approaches have different shortcomings and eligibility criteria.

There are many variations of uterine conservative surgery, which include prophylactic balloon occlusion or major vascular intervention (such as the triple P procedure)[28]. However, many of these studies did not compare their interventions to hysterectomy and, therefore, were excluded from our review. The studies that were eventually included were not randomized and almost all were at high risk of bias, making it impossible to derive any conclusions about prophylactic vascular interventions. Recently, conflicting meta-analyses and randomized controlled trial results reported benefit or no effect of prophylactic balloon occlusion in women undergoing hysterectomy for PAS[29,30]. It should be clear that the studies suggesting benefit were mostly nonrandomized (inadequate to prove superiority), and the trials had limited sample

sizes, hence, this is an ongoing topic of discussion that could be relevant for conservative surgical management of PAS as well.

Moreover, management of PAS requires careful consideration due to the complexity of interventions and the potential for intraoperative complications, particularly visceral organ injuries. Urological complications occur in approximately 20% of all hysterectomies performed in PAS cases[31]. Our review suggests with low certainty a lower risk of bladder injury (although not adequately designed to prove such benefit) and no increased risk of ureteric injury. These findings could represent a significant advancement and warrant further investigation in future trials.

CONCLUSION

Implications for practice

Conservative uterine surgery in women diagnosed with placenta accreta spectrum disorders, and with sufficiently healthy lower anterior uterine wall and uterine circumference, may not lead to higher blood loss, number of packs of red blood cells transfused, intraoperative visceral organ injury, and duration of surgery compared to hysterectomy. Therefore, uterus preservation is possible without the risk of substantial harm in critical outcomes likely increasing. This surgical procedure is not possible in all women diagnosed with PAS, especially in the presence of vesicouterine fibrosis.

Implications for research

Further research should seek to increase the total sample size of randomized trials comparing uterine conservative surgery to hysterectomy in order to minimize imprecision on confidence interval boundaries and review information size. Additionally, it would be ideal to determine whether there are specific variations of conservative surgery, especially involving

prophylactic balloon occlusion, that result in better surgical outcomes. At present, our results suggest that conservative management does not result in substantially increased harm to women compared to hysterectomy, but more precise estimates would allow the determination of possible benefit or non-inferiority.

DECLARATIONS

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The data can be shared upon request

Competing interests

The authors declare that they have no competing interests

Funding

No specific funding was available for the project

Authors' contributions

GML was responsible for conceptualizing the work, data acquisition, analysis, and writing the manuscript. GAMC was responsible for conceptualizing the work and writing the manuscript. PVMG was responsible for data analysis and revising the manuscript.

Acknowledgments

Not applicable

REFERENCES

1. Matsuzaki S, Mandelbaum RS, Sangara RN, et al. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States. *Am J Obstet Gynecol*. 2021;225(5):534.e1-534.e38. doi:10.1016/j.ajog.2021.04.233
2. Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E, FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. *Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet*. 2018;140(3):291-298. doi:10.1002/ijgo.12410
3. Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. *Am J Obstet Gynecol*. 2022;226(6):839.e1-839.e24. doi:10.1016/j.ajog.2021.12.013
4. Palacios Jaraquemada JM, Pesaresi M, Nassif JC, Hermosid S. Anterior placenta percreta: surgical approach, hemostasis and uterine repair. *Acta Obstet Gynecol Scand*. 2004;83(8):738-744. doi:10.1111/j.0001-6349.2004.00517.x
5. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898. doi:10.1136/bmj.l4898
6. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919. doi:10.1136/bmj.i4919
7. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res*. 2018;27(6):1785-1805. doi:10.1177/0962280216669183
8. Viechtbauer W. Conducting meta-analyses in {R} with the {metafor} package. *J Stat Softw*. 2010;36(3).
9. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health*. 2019;22(4):153-160. doi:10.1136/ebmental-2019-300117

10. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). Published online 2013. https://gdt.gradepro.org/app/handbook/handbook.html
11. Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. *J Clin Epidemiol*. 2022;150:216-224. doi:10.1016/j.jclinepi.2022.07.014
12. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S, FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. *Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet*. 2019;146(1):20-24. doi:10.1002/ijgo.12761
13. Nieto-Calvache ÁJ, Aryananda RA, Palacios-Jaraquemada JM, et al. One-step conservative surgery vs hysterectomy for placenta accreta spectrum: a feasibility randomized controlled trial. *Am J Obstet Gynecol MFM*. 2024;6(6):101333. doi:10.1016/j.ajogmf.2024.101333
14. Nieto-Calvache AJ, Palacios-Jaraquemada JM, Aryananda R, et al. How to perform the one-step conservative surgery for placenta accreta spectrum move by move. *Am J Obstet Gynecol MFM*. 2023;5(2):100802. doi:10.1016/j.ajogmf.2022.100802
15. Paping A, Bluth A, Al Naimi A, et al. Opportunities for, and barriers to, uterus-preserving surgical techniques for placenta accreta spectrum. *Acta Obstet Gynecol Scand*. Published online May 2, 2024. doi:10.1111/aogs.14855
16. Abouda HS, Aloui H, Azouz E, et al. New surgical technique for managing placenta accreta spectrum and pilot study of the “CMNT PAS” study. *AJOG Glob Rep*. 2025;5(1):100430. doi:10.1016/j.xagr.2024.100430
17. van Beekhuizen HJ, Stefanovic V, Schwickert A, et al. A multicenter observational survey of management strategies in 442 pregnancies with suspected placenta accreta spectrum. *Acta Obstet Gynecol Scand*. 2021;100 Suppl 1(Suppl 1):12-20. doi:10.1111/aogs.14096
18. Vuong ADB, Pham TH, Pham XTT, et al. Modified one-step conservative uterine surgery (MOSCUS) versus cesarean hysterectomy in the management of placenta accreta spectrum: A single-center retrospective analysis based on 619 Vietnamese pregnant women. *Int J Gynaecol*

Obstet Off Organ Int Fed Gynaecol Obstet. 2024;165(2):723-736. doi:10.1002/ijgo.15220

19. Aryananda RA, Duvekot JJ, Van Beekhuizen HJ, Cininta NI, Ariani G, Dachlan EG. Transabdominal and transvaginal ultrasound findings help to guide the clinical management of placenta accreta spectrum cases. *Acta Obstet Gynecol Scand*. 2024;103(1):93-102. doi:10.1111/aogs.14715
20. Aryananda RA, Aditiawarman A, Gumilar KE, et al. Uterine conservative-resective surgery for selected placenta accreta spectrum cases: Surgical-vascular control methods. *Acta Obstet Gynecol Scand*. 2022;101(6):639-648. doi:10.1111/aogs.14348
21. Mohammad Jafari R, Najafian M, Barati M, Saadati N, Jalili Z, Poolad A. Comparison of uterine preservation versus hysterectomy in women with placenta accreta: A cross-sectional study. *Int J Reprod Biomed*. 2022;20(9):739-744. doi:10.18502/ijrm.v20i9.12063
22. Durukan H, Durukan ÖB, Yazıcı FG. Placenta accreta spectrum disorder: a comparison between fertility-sparing techniques and hysterectomy. *J Obstet Gynaecol J Inst Obstet Gynaecol*. 2021;41(3):353-359. doi:10.1080/01443615.2020.1755629
23. Üstünyurt E. Local uterine resection with Bakri balloon placement in placenta accreta spectrum disorders. *Turk J Obstet Gynecol*. 2020;17(2):108-114. doi:10.4274/tjod.galenos.2020.82652
24. Reeves B, Deeks J, Higgins J, Shea B, Tugwell P, Wells G. Chapter 24: Including non-randomized studies on intervention effects. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Published online 2023. Accessed December 26, 2023. https://training.cochrane.org/handbook/current/chapter-24
25. Javinani A, Qaderi S, Hessami K, et al. Delivery outcomes in the subsequent pregnancy following the conservative management of placenta accreta spectrum disorder: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2024;230(5):485-492.e7. doi:10.1016/j.ajog.2023.10.047
26. Zhao H, Liu C, Fu H, Abeykoon SDI, Zhao X. Subsequent pregnancy outcomes and risk factors following conservative treatment for placenta accreta spectrum: a retrospective cohort study. *Am J Obstet Gynecol MFM*. 2023;5(12):101189. doi:10.1016/j.ajogmf.2023.101189
27. Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. *Am J Obstet Gynecol*.

2022;226(6):839.e1-839.e24. doi:10.1016/j.ajog.2021.12.013

28. Piñas-Carrillo A, Chandraharan E. Conservative surgical approach: The Triple P procedure. *Best Pract Res Clin Obstet Gynaecol*. 2021;72:67-74. doi:10.1016/j.bpobgyn.2020.07.009
29. Bonsen LR, Sleijpen K, Hendriks J, et al. Prophylactic Radiologic Interventions for Postpartum Hemorrhage Control in Women With Placenta Accreta Spectrum Disorder. *Obstet Gynecol*. 2024;144(3):315-327. doi:10.1097/AOG.0000000000005662
30. Yu SCH, Cheng YKY, Tse WT, et al. Perioperative prophylactic internal iliac artery balloon occlusion in the prevention of postpartum hemorrhage in placenta previa: a randomized controlled trial. *Am J Obstet Gynecol*. 2020;223(1):117.e1-117.e13. doi:10.1016/j.ajog.2020.01.024
31. Lucidi A, Jauniaux E, Hussein AM, et al. Urological complications in women undergoing Cesarean section for placenta accreta spectrum disorders: systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2023;62(5):633-643. doi:10.1002/uog.26299